Table 1 Baseline characteristics of patients (intent-to-treat population) randomized to receive subcutaneous IFNβ-1a or IFNβ-1b
Baseline characteristic | IFNβ-1a (N= 65) | IFNβ-1b (N= 64) |
|---|---|---|
Age, years | ||
Mean (SD) | 40.26 (9.80) | 40.78 (9.56) |
Median (range) | 40.0 (20–60) | 40.0 (19–59) |
Female, n (%) | 46 (70.8) | 44 (68.8) |
Race, n (%) | ||
White | 55 (84.6) | 58 (90.6) |
Black | 6 (9.2) | 5 (7.8) |
Asian | 2 (3.1) | 0 |
Other | 2 (3.1) | 1 (1.6) |
BMI, kg/m2, mean (SD) | 29.66 (6.76) | 30.23 (8.35) |
Classification of MS, n (%) | ||
Poser criteria | 19 (29.2) | 17 (26.6) |
McDonald criteria | 46 (70.8) | 47 (73.4) |
Time since first signs and/or symptoms of MS (onset), years, mean (SD) | 4.51 (6.70) | 5.74 (6.66) |
Time since MS diagnosis, years, mean (SD) | 1.01 (2.35) | 1.93 (4.02) |
Patients with no relapse during the 12 months before informed consent, n (%) | 10 (15.4) | 14 (21.9) |
Relapses per patient,a mean (SD) | 1.36 (0.52) | 1.30 (0.46) |
Time since last relapse,a months, mean (SD) | 3.52 (2.94) | 4.01 (2.93) |
Number of steroid courses required for relapses per patient,a mean (SD) | 0.53 (0.60) | 0.46 (0.50) |
Patients who required ≥1 course of steroids,a n (%) | 26 (47.3) | 23 (46.0) |